ArticleAntimicrobial resistance and infection control2025
Impact of the COVID-19 pandemic on surgical site infections: a multi-center study evaluating incidence, pathogen distribution, and antimicrobial resistance patterns.
Article in Antimicrobial resistance and infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Interpreting Abdominal Surgical-Site Infection Trends Across the COVID-19 Shock: A Critical Narrative Review and the SSI Signal-Validity Framework.Life (Basel, Switzerland) · 2026Review
- Incidence, microbiological spectrum, and antimicrobial resistance patterns of surgical site infections at a tertiary care hospital in Pakistan: a retrospective observational study.BMC infectious diseases · 2026Observational
- Surgical Site Infections and Antimicrobial Resistance: Six Years of Data from a Western Romanian Hospital.Medicina (Kaunas, Lithuania) · 2026Article
- Recent COVID-19 Infection Increases Complication Risk After Body-Contouring Surgery.Aesthetic surgery journal. Open forum · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical site infections (SSIs) are among the most significant concerns in healthcare settings, presenting challenges in patient management and healthcare outcomes. The emergence of the COVID-19 pandemic has further complicated the landscape of infectious disease epidemiology, impacting the distribution and resistance characteristics of pathogens responsible for SSIs. Understanding these dynamics is essential for improving infection prevention and treatment strategies.
methodsThis retrospective multi-center study included 17 hospitals in Turkey, analyzing SSI cases from January 2019 to January 2023. The study was divided into three phases: pre-pandemic (January 2019 - March 2020), early pandemic (March 2020 - January 2022), and late pandemic (January 2022 - January 2023). We assessed demographic and clinical characteristics, pathogen distributions, and resistance rates, focusing on multidrug-resistant (MDR) pathogens.
resultsA total of 2,058 patients with SSIs were included. The SSI rate increased from 0.79% in 2019 to 0.87% in 2020, then decreased to 0.46% in 2021 and 0.50% in 2022. The most prevalent pathogens were E. coli (21.9%) and K. pneumoniae (14.6%). Resistance to meropenem in K. pneumoniae rose from 23% pre-pandemic to 33% post-pandemic, while ceftazidime-avibactam resistance surged from 6 to 43%. P. aeruginosa showed increased quinolone resistance from 18 to 27%, with colistin resistance rising to 13% in the late pandemic phase.
conclusionsThis study highlights the significant impact of the COVID-19 pandemic on SSIs in Turkey, revealing concerning trends in antibiotic resistance among key pathogens. Ongoing surveillance and enhanced infection control measures are essential to address these challenges and improve patient outcomes in the post-pandemic era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.